Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Biomea Fusion, Inc.

NASDAQ: BMEA · Life Sciences · 4 alerts · CIK 1840439

Share price
$0.5201Close, Nov 16
Market cap
$37.8M
Shares outstanding
72.68MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Biomea Fusion, Inc. filings on SEC EDGAR ↗

4:32 PM ET 10-Q
Financial Results

Biomea Fusion Q3 2026 Results: Net Loss of $6.18M, Loss Narrows

Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule therapies for diabetes and obesity. The filing indicates substantial doubt about the company's ability to continue as a going concern, highlighting a critical need for additional capital to fund ongoing research and development of its lead candidates, icovamenib and BMF-650.

Key figure
Net loss $6.18M
4:28 PM ET 8-K
Financial Results

Biomea Fusion Financial Results

Biomea Fusion reported financial results for the third quarter of 2026, highlighting the completion of enrollment in its Phase II COVALENT-211 trial for icovamenib in type 2 diabetes. The company also reported positive Phase I results for its oral GLP-1 RA candidate, BMF-650, and projected its cash runway into the second quarter of 2027.

Term
Q3 2026

“The third quarter was marked by meaningful execution across both of our clinical programs. We completed enrollment in our first diabetes Phase II clinical trial, COVALENT-211, and continue to advance enrollment in our Phase II COVALENT-212 clinical trial, bringing us closer to important Phase II data readouts for icovamenib in two distinct diabetes populations that we estimate represent over 30% of treated patients with diabetes in the U.S.”

Mick Hitchcock, Ph.D., Interim Chief Executive Officer

“We also reported first-in-human results for BMF-650, providing initial clinical support for our design hypothesis, in that BMF-650 achieved meaningful weight reduction while limited GI side effects were observed, all of which were Grade 1 AEs at the highest dose level.”

Mick Hitchcock, Ph.D., Interim Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.